Understanding why some patients become resistant to thalidomide treatments
Defining mechanisms of thalidomide analog resistance
['FUNDING_CAREER'] · BRIGHAM AND WOMEN'S HOSPITAL · NIH-10876390
This study is looking into why some patients with multiple myeloma and other blood cancers don’t respond well to thalidomide and similar treatments, and it aims to find ways to make these therapies work better for you.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM AND WOMEN'S HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10876390 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind resistance to thalidomide and its analogs in patients with multiple myeloma and other blood cancers. The team will utilize a novel mass spectrometry assay to measure specific proteins related to drug resistance and explore genetic factors that may influence treatment outcomes. By identifying key pathways involved in resistance, the research aims to develop strategies to enhance the effectiveness of these important therapies for patients. This work is led by Dr. Adam Sperling at the Dana-Farber Cancer Institute.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with multiple myeloma or other hematologic malignancies who have experienced resistance to thalidomide or its analogs.
Not a fit: Patients who have not been treated with thalidomide or its analogs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients who currently do not respond to thalidomide therapies.
How similar studies have performed: Previous research has shown success in identifying mechanisms of drug resistance in cancer therapies, suggesting that this approach may yield valuable insights.
Where this research is happening
BOSTON, UNITED STATES
- BRIGHAM AND WOMEN'S HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SPERLING, ADAM — BRIGHAM AND WOMEN'S HOSPITAL
- Study coordinator: SPERLING, ADAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.